The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study
Open accessAbstract
Summary: Background: Empagliflozin is a sodium‐glucose‐cotransporter‐2 inhibitor that improves cardiovascular risk and promotes weight loss in patients with type‐2 diabetes. Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascular risk; therefore, empagliflozin may be of benefit for these women. The aim of this study was to compare the effects of empagliflozin vs metformin on anthropometric and body composition, hormonal and metabolic parameters in women with PCOS. Materials and methods: A randomized open‐label study was conducted in women with PCOS who were randomized to either empagliflozin 25 mg (n = 19) or metformin 1500 mg (n = 20) daily for 12 weeks. The main outcomes assessed were changes in anthropometric and body composition, hormonal and metabolic parameters. Results: Univariate analysis showed significant differences in weight (empagliflozin: −1.4 ± 3.2% vs metformin: 1.2 ± 2.3%; P = 0.006), body mass index (empagliflozin: −1.4 ± 3.2% vs metformin: 1.1 ± 2.2%; P = 0.006), waist circumference (empagliflozin: −1.6 ± 2.8% vs metformin: 0.2 ± 2.1%; P = 0.029) and hip circumference (empagliflozin: −2.0 ± 3.0% vs metformin: 1.1 ± 1.9%; P = 0.001), basal metabolic rate (empagliflozin: −1.8 ± 2.9% vs metformin: 0.1 ± 1.9%, P = 0.024) and fat mass (empagliflozin: −0.7 ± 4.9% vs metformin, 3.2 ± 5.0%; P = 0.023) between the empagliflozin and the metformin groups. These differences were confirmed in linear regression analysis after adjustment for relevant covariates. There were no significant changes in hormonal or metabolic parameters between both groups. Conclusion: There was a significant improvement in anthropometric parameters and body composition, in overweight and obese women with PCOS after 12 weeks of treatment with empagliflozin compared to metformin, although no changes were seen in hormonal or metabolic parameters.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Only a favourable effect of empagliflozin on body weight (empagliflozin –1.4 kg ± 3.2% vs. metformin: 1.2 kg ± 2.3%; p = 0.006) and BMI (empagliflozin: −1.4 ± 3.2% vs. metformin: 1.1 ± 2.2%; p = 0.006) has been observed.”
From From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management (2020) · cites this paper as [67]
In the citing paper
“May be because of the short period of observation or the small sample size, no changes in metabolic parameters (insulin, fasting glucose, and HOMA‐IR) have been observed from the baseline, nor on hormonal profile for both drugs.”
From From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management (2020) · cites this paper as [67]
In the citing paper
“May be because of the short period of observation or the small sample size, no changes in metabolic parameters (insulin, fasting glucose, and HOMA‐IR) have been observed from the baseline, nor on hormonal profile for both drugs.”
From From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management (2020) · cites this paper as [67]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2350 · Cited by 1,919
Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., & the International PCOS Network (2018) · Clinical Endocrinology · doi:10.1111/cen.13795 · Cited by 1,823
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134
Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D. R., & Tsapas, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00007 · Cited by 911
Fitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv728 · Cited by 907
Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1096 · Cited by 740
Vallon, V., & Thomson, S. C. (2017) · Diabetologia · doi:10.1007/s00125-016-4157-3 · Cited by 635
Xu, L., Nagata, N., Nagashimada, M., Zhuge, F., Ni, Y., Chen, G., Mayoux, E., Kaneko, S., & Ota, T. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.05.028 · Cited by 512
Cited by
Sorted by citations
Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing
Sadeghi, H. M., Adeli, I., Calina, D., Docea, A. O., Mousavi, T., Daniali, M., Nikfar, S., Tsatsakis, A., & Abdollahi, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020583 · Cited by 445
Sargeant, J. A., Henson, J., King, J. A., Yates, T., Khunti, K., & Davies, M. J. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.3.247 · Cited by 231
The Current and Potential Therapeutic Use of Metformin—The Good Old Drug
Drzewoski, J., & Hanefeld, M. (2021) · Pharmaceuticals · doi:10.3390/ph14020122 · Cited by 173
Polycystic ovarian syndrome-current pharmacotherapy and clinical implications
Rashid, R., Mir, S. A., Kareem, O., Ali, T. F., Ara, R., Malik, A., Amin, F., & Bader, G. N. (2022) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2021.11.009 · Cited by 180
Bednarz, K., Kowalczyk, K., Cwynar, M., Czapla, D., Czarkowski, W., Kmita, D., Nowak, A., & Madej, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084334 · Cited by 148
Teo, Y. H., Teo, Y. N., Syn, N. L. X., Kow, C. S., Yoong, C. S. Y., Tan, B. Y., Yeo, T., Lee, C., Lin, W., & Sia, C. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019463 · Cited by 141
Polycystic Ovary Syndrome: Pathophysiology and Therapeutic Opportunities
Dong, J., & Rees, D. A. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2023-000548 · Cited by 123
A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome
Abdalla, M. A., Deshmukh, H., Atkin, S. L., & Sathyapalan, T. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820938305 · Cited by 115
Self-citationPolycystic ovary syndrome and type 2 diabetes mellitus: A state-of-the-art review
Livadas, S., Anagnostis, P. G., Bosdou, J. Κ., Bantouna, D., & Paparodis, R. D. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i1.5 · Cited by 111
Elkind-Hirsch, K. E., Chappell, N., Seidemann, E., Storment, J., & Bellanger, D. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab408 · Cited by 96
Zhang, S., Qi, Z., Wang, Y., Song, D., & Zhu, D. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1203666 · Cited by 87
Endocrine disorders and fertility and pregnancy: An update
Bednarska‐Czerwińska, A., Zmarzły, N., Morawiec, E., Panfil, A., Bryś, K., Czarniecka, J., Остенда, А., Dziobek, K., Sagan, D., Boroń, D., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.970439 · Cited by 73
Zhang, J., Xing, C., Cheng, X., & He, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1003238 · Cited by 60
Tan, S., Ignatenko, S., Wagner, F. D., Dokras, A., Seufert, J., Zwanziger, D., Dunschen, K., Zakaria, M., Huseinovic, N., Basson, C. T., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14495 · Cited by 57
Lee, M. M. Y., Petrie, M. C., McMurray, J. J. V., & Sattar, N. A. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.311904 · Cited by 57
Pruett, J. E., Everman, S. J., Hoang, N., Salau, F., Taylor, L. C., Edwards, K. S., Hosler, J. P., Huffman, A. M., Romero, D. G., & Cardozo, L. L. Y. (2022) · Biology of Sex Differences · doi:10.1186/s13293-022-00455-x · Cited by 46
Recent advances in emerging PCOS therapies
Glendining, K. A., & Campbell, R. E. (2023) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102345 · Cited by 45
Cai, M., Shao, X., Xing, F., Zhang, Y., Gao, X., Zeng, Q., Dilimulati, D., Qu, S., & Zhang, M. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14583 · Cited by 44
Pruett, J. E., Fernandez, E. D. T., Everman, S. J., Vinson, R. M., Davenport, K., Logan, M. K., Ye, S. A., Romero, D. G., & Cardozo, L. L. Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052576 · Cited by 43
Xu, Q., Zhang, J., Lu, Y., & Wu, L. Y. (2024) · iScience · doi:10.1016/j.isci.2024.108783 · Cited by 43
Polycystic ovary syndrome and obesity: clinical aspects and nutritional management
Frías-Toral, E., Garcia-Velasquez, E., Carignano, M. D. L. A., Veintimilla, D. R., ALVARADO-AGUILERA, I., & Litardo, N. B. (2021) · Minerva Endocrinology · doi:10.23736/s2724-6507.21.03349-6 · Cited by 41
Pani, A., Gironi, I., Di Vieste, G., Mion, E., Bertuzzi, F., & Pintaudi, B. (2020) · International Journal of Endocrinology · doi:10.1155/2020/6276187 · Cited by 38
Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS
Cignarella, A., Mioni, R., Sabbadin, C., Dassie, F., Parolin, M., Vettor, R., Barbot, M., & Scaroni, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249554 · Cited by 36
Marinkovic-Radosevic, J., Cigrovski Berkovic, M., Kruezi, E., Bilic-Curcic, I., & Mrzljak, A. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i7.932 · Cited by 35
Sinha, B., & Ghosal, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.830401 · Cited by 36
Current and emerging drug treatment strategies for polycystic ovary syndrome
Helvaci, N., & Yildiz, B. O. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2108702 · Cited by 35
Yang, S., Zhao, L., He, W., & Mi, Y. (2022) · Drugs · doi:10.1007/s40265-022-01779-z · Cited by 33
Buttice, L., Ghani, M., Suthakar, J., Gnanalingham, S., Carande, E. J., Kennedy, B. W. C., Pitcher, A., Gamble, J. H. P., Ahmad, M., Lewis, A., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15586 · Cited by 37
Myopathy Associated With Statins and SGLT2 – A Review of Literature
Gupta, R., Alcantara, R., Popli, T., Mahajan, S., Tariq, U., Dusaj, R., & Malik, A. H. (2020) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2020.100765 · Cited by 32
Quercetin and polycystic ovary syndrome
Ma, C., Xiang, Q., Song, G., & Wang, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1006678 · Cited by 36
Bilgin, S., Kurtkulağı, Ö., Duman, T. T., Tel, B. M. A., Kahveci, G. B., Kiran, M., Erge, E., & Aktaş, G. (2021) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02761-6 · Cited by 28
Zahid, S., Khan, M. Z., Gowda, S. N., Faza, N. N., Honigberg, M. C., Vaught, A. “. J., Guan, C. S., Minhas, A., & Michos, E. D. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.025839 · Cited by 28
Rakic, D., Jakovljevic, V. L., Jović, N., Ilic, M. B., Dimitrijević, A., Vulovic, T. S., Arsenijević, P. S., Sretenovic, J. Z., Muric, M. D., Фисенко, В. П., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11040998 · Cited by 26
Javed, Z., Papageorgiou, M., Madden, L. A., Rigby, A. S., Kilpatrick, E. S., Atkin, S. L., & Sathyapalan, T. (2020) · Endocrine Connections · doi:10.1530/ec-20-0173 · Cited by 24
Self-citationNisa, K. U., Tarfeen, N., Mir, S. A., Waza, A. A., Ahmad, M. B., & Ganai, B. A. (2023) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-023-01130-7 · Cited by 28
Possible Effect of Polycystic Ovary Syndrome (PCOS) on Cardiovascular Disease (CVD): An Update
Profili, N. I., Castelli, R., Gidaro, A., Manetti, R., Maioli, M., Petrillo, M., Capobianco, G., & Delitala, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030698 · Cited by 28
Teo, Y. H., Yoong, C. S. Y., Syn, N. L. X., Teo, Y. N., Cheong, J. Y. A., Lim, Y. C., Lee, C., Yeo, T., Chai, P., Wong, R. C.-C., et al. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03147-4 · Cited by 23
Cardiometabolic effects of SGLT2 inhibitors on polycystic ovary syndrome
Lempesis, I. G., Apple, S. J., Duarte, G., Palaiodimos, L., Kalaitzopoulos, D. R., Dalamaga, Μ., & Kokkinidis, D. G. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3682 · Cited by 24
Post, A., Groothof, D., Eisenga, M. F., & Bakker, S. J. L. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051603 · Cited by 22
SGLT-2 inhibitors in obesity and its associated cardiometabolic disorders: where do we stand?
Vallianou, N. G., Tsilingiris, D., Kounatidis, D. C., Lempesis, I. G., Karampela, Ι., & Dalamaga, Μ. (2022) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16342 · Cited by 23
Papaetis, G. S. (2021) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2021.105314 · Cited by 24
Medical Treatment and Comorbidity in Polycystic Ovary Syndrome: An Updated Review
Glintborg, D., & Andersen, M. (2020) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2020.02.014 · Cited by 20
Novel Antidiabetic Medications in Polycystic Ovary Syndrome
Somagutta, M. K. R., Jain, M. S., Uday, U., Pendyala, S. K., Mahadevaiah, A., Mahmutaj, G., Jarapala, N., Gad, M. A., Srinivas, P. M., Sasidharan, N., et al. (2022) · Discoveries · doi:10.15190/d.2022.4 · Cited by 20
Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update
Kalra, S., Shetty, K., Nagarajan, V. B., & Ved, J. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00789-y · Cited by 19
Sridharan, K., & Sivaramakrishnan, G. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01730-8 · Cited by 21
Fakhrolmobasheri, M., Abhari, A. P., Manshaee, B., Heidarpour, M., Shafie, D., Mohammadbeigi, E., Mozafari, A. M., & Mazaheri‐Tehrani, S. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01981-1 · Cited by 17
Mahmoud, M. M., Rashed, L. A., Soliman, S. A. M., Sayed, S. M., Kamel, O., Kamar, S. S., & Hussien, R. E. S. (2023) · Physiological Reports · doi:10.14814/phy2.15858 · Cited by 15
Zhang, L., Wang, Z., Kong, L., Liu, H., Ma, Z., Xu, M., Yushanjiang, S., Yuan, D., & Yu, L. (2023) · Reproductive Sciences · doi:10.1007/s43032-023-01415-5 · Cited by 15
Dapagliflozin partially restores reproductive function in MC4R KO obese female mice
Cui, L., Tan, C., Huang, L., Wang, W., Huang, Z., Geng, F., Wu, M., Chen, X., Cowley, M. A., Roelfsema, F., et al. (2022) · Journal of Endocrinology · doi:10.1530/joe-21-0449 · Cited by 15
Chen, X., Wan, Y., & Xie, L. (2025) · Biology of Reproduction · doi:10.1093/biolre/ioaf197 · Cited by 15
Baranowska-Bik, A. (2022) · Endokrynologia Polska · doi:10.5603/ep.a2022.0047 · Cited by 19
Bo, Y., Zhao, J., Liu, C., & Yu, T. (2025) · BMC Women s Health · doi:10.1186/s12905-025-03594-6 · Cited by 17
Clinico-Metabolic Profile in Lean Versus Obese Polycystic Ovarian Syndrome Women
Makhija, N., Tayade, S. A., Toshniwal, S., & Tilva, H. (2023) · Cureus · doi:10.7759/cureus.37809 · Cited by 12
Multiple Benefits of Empagliflozin in PCOS: Evidence from a Preclinical Rat Model
Rakic, D., Jakovljevic, V. L., Zivkovic, V., Uzelac, J. J., Jovic, N., Muric, M. D., Pindović, B., Dimitrijević, A., Arsenijević, P. S., Rakic, J., et al. (2024) · Pathophysiology · doi:10.3390/pathophysiology31040041 · Cited by 11
Chen, X., Huang, L., Cui, L., Xiao, Z., Xiong, X., & Chen, C. (2022) · The Journal of Physiology · doi:10.1113/jp283259 · Cited by 11
Porth, R., Oelerich, K., & Sivanandy, M. S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13041056 · Cited by 11
Roy, M., Parveen, R., Khan, P. M., Majid, H., Pathak, M., Saxena, R. K., & Agarwal, N. B. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2407513 · Cited by 10
Pruett, J. E., Romero, D. G., & Cardozo, L. L. Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.951099 · Cited by 10
Kumbhar, P., Chavan, R., Darekar, S., Kolekar, K. A., Sequeira, A., Vishwas, S., Gupta, G., Paudel, K. R., Singh, S. K., Dua, K., et al. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03578-7 · Cited by 10
Shi, Y., Si, Y., Fu, R., Zhang, M., Jiang, K., Dai, W., Shen, J., Li, X., & Yuan, Y. (2022) · Endokrynologia Polska · doi:10.5603/ep.a2021.0102 · Cited by 9
Ahsan, M., & Mallick, A. K. (2025) · The Indian Journal of Medical Research · doi:10.25259/ijmr_497_2025 · Cited by 8
Chen, L., Liu, Y., Zhang, L., Li, J., Xiong, W.-Q., Li, T., Ding, H., & Li, B. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1294339 · Cited by 10
The impact of androgen levels on serum metabolic profiles in patients with polycystic ovary syndrome
Zhao, T., Xinghua, T., Xiao, X., Lingchuan, L., Wu, X., & Yuan, T. (2024) · Gynecological Endocrinology · doi:10.1080/09513590.2024.2352136 · Cited by 8
Impact of tofogliflozin on hepatic outcomes: a systematic review
Pathak, M., Parveen, R., Khan, P. M., Saha, N., & Agarwal, N. B. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03537-w · Cited by 8
Das polyzystische Ovarsyndrom als genderspezifischer kardiometabolischer Risikofaktor
van Baal, L., & Tan, S. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01529-7 · Cited by 7
Leon, L. I. R., Anastasopoulou, C., & Mayrin, J. V. (2021) · StatPearls · Cited by 7
Mrabet, H. E., Salem, H. B., Ach, T., Abdelkarim, A. B., & Alaya, W. (2024) · SAGE Open Medicine · doi:10.1177/20503121241308997 · Cited by 6
Chen, X., Xiao, Z., Dai, N., & Fan, M. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1457268 · Cited by 6
Unraveling PCOS therapies: Pharmacotherapeutic strategies and emerging therapeutic targets
Shirasath, K. R., Ahmed, N. Z., Kumar, P., Alam, S., Karwasra, R., Goyal, S. N., & Agrawal, Y. O. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156245 · Cited by 7
Jobanputra, R., Sargeant, J. A., Plekhanova, T., James, E., Almaqhawi, A., Webb, D. R., Davies, M. J., & Yates, T. E. (2026) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70194 · Cited by 8
Effects of a New Group of Antidiabetic Drugs in Metabolic Diseases
Sanz‐Cánovas, J., Ricci, M., Cobos-Palacios, L., Sampalo, A. L., Hernández-Negrín, H., Vázquez-Márquez, M., Mancebo-Sevilla, J. J., Álvarez-Recio, E., Lopez-Carmona, M. D., Velasco, M. Á. P., et al. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2402036 · Cited by 6
Kamrul-Hasan, A. B. M., Mondal, S., Aalpona, F. T. Z., Nagendra, L., & Dutta, D. (2025) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2025.21.1.2 · Cited by 5
Peng, H., Ren, J., Zhao, Y., Fang, X., Wang, X., Liu, C., & Wan, Z. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112235 · Cited by 7
Abdelhameed, A. M., Eissa, M., Thompson, K., Edwards, K. S., Hoang, N., Rezq, S., Cornelius, D. C., Romero, D. G., & Cardozo, L. L. Y. (2025) · Endocrinology · doi:10.1210/endocr/bqaf173 · Cited by 4
Wu, X., Yi, W., & Liu, X. (2026) · Biomedicines · doi:10.3390/biomedicines14010213 · Cited by 6
Taghipour, F., Samadian, H., Dalirfardouei, R., Asl, S. S., Barati, N., & Artimani, T. (2025) · Steroids · doi:10.1016/j.steroids.2025.109688 · Cited by 4
Yang, X., Luo, H., Li, Q., Zhu, W., Fu, L., Chen, L., Li, X., Su, H., Zhang, L., & Huang, Y. (2025) · The FASEB Journal · doi:10.1096/fj.202502661r · Cited by 4
Targeting metabolism in the management of PCOS: Metformin and beyond
Oğuz, S. H., Şendur, S. N., Ünlütürk, U., & Yıldız, B. O. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823045-9.00006-7 · Cited by 5
Pharmacological Management of Obesity in Patients with Polycystic Ovary Syndrome
Kourtidou, C., & Τζιόμαλος, Κ. (2023) · Biomedicines · doi:10.3390/biomedicines11020496 · Cited by 6
The Efficacy of Metformin and Exenatide in Polycystic Ovary Syndrome (PCOS) Patients
Kesavan, S., Chaudhry, G.-E.-S., Akim, A. M., & Ranneh, Y. (2023) · Ars Pharmaceutica (Internet) · doi:10.30827/ars.v64i2.27302 · Cited by 4
Park, M.-J., Kim, E., Ok, J.-M., Choi, K.-H., & Lim, Y.-W. (2022) · Journal of Korean Medicine for Obesity Research · doi:10.15429/jkomor.2022.22.2.136 · Cited by 4
Afrăsânie, I., Matei, I. T., Leancă, S. A., Chetran, A., Costache, A. D., Afrăsânie, V.-A., Dmour, B.-A., Crișu, D., Bădescu, M. C., Șerban, L., et al. (2023) · Life · doi:10.3390/life13020443 · Cited by 4
Management of Hypertension in Patients With Polycystic Ovarian Syndrome: A Mini-Review
Liaghatdar, A., Mazaheri‐Tehrani, S., & Fakhrolmobasheri, M. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000635 · Cited by 4
Matuszewski, W., Tomaszek, L., Szklarz, M., Górny, J. M., Kordas, B., Rutkowska, J., & Juranek, J. K. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186348 · Cited by 3
Sharif, H., Arsalan, S., Rehman, N., Muzammil, A., Hatif, F., Wasti, F., Rehman, S., Mohsin, N., Nasir, R., & Omair, W. (2025) · BMC Women s Health · doi:10.1186/s12905-025-04091-6 · Cited by 4
Zhang, J., Xing, C., & He, B. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-058260 · Cited by 3
Newer Glucose-Lowering Medications and Potential Role in Metabolic Management of PCOS
Anam, A. K., & Inzucchi, S. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-92589-5_26 · Cited by 3
Management of insulin resistance in PCOS
Cherian, K. E., & Paul, T. V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00015-3 · Cited by 3
Tao, S., Guo, S., & Tong, N. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2952 · Cited by 2
Revisiting Metformin in the Management of Polycystic Ovary Syndrome (PCOS)
Telagarapu, V. M. L., Nallamothu, P. D., Telagarapu, V. M. L., Nalluri, S., Nathani, S., Kopani, C. P., Yarraguntla, V., & Vyasalapu, S. (2025) · Cureus · doi:10.7759/cureus.88216 · Cited by 7
Gohary, D. S. E. E., Ismail, M. M., Khayat, A. M. E., & Elbohoty, S. B. (2023) · Journal of Medicine in Scientific Research · doi:10.59299/2537-0928.1025 · Cited by 2
Abiri, B., Ahmadi, A. R., Hosseinpanah, F., Valizadeh, A., Zarghi, A., & Valizadeh, M. (2024) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-024-01692-2 · Cited by 2
Bossi, A. C., Forloni, F., & Colombelli, P. L. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00943-6 · Cited by 2
Buch, A., Eldor, R., Kis, O., Ben‐Yehuda, A., Green, G., Greenman, Y., & Barak, S. (2025) · Heliyon · doi:10.1016/j.heliyon.2024.e41593 · Cited by 1
Lin, J., Yang, R., Zhuang, J., Zhang, W., Tong, Q., Liu, J., Kang, Y., & Yuan, Y. (2026) · Journal of Ovarian Research · doi:10.1186/s13048-026-02078-x · Cited by 3
Aghajanpoor, M., Gholampourdehaki, M., Mosaed, R., Mirzaii‐Dizgah, I., & Vosughi, A. (2024) · Annals of Military and Health Sciences Research · doi:10.5812/amh-144009 · Cited by 1
Androgens and Cardiovascular Risk Factors in Polycystic Ovary Syndrome
Cardozo, L. L. Y., Huffman, A. M., Pruett, J. E., & Romero, D. G. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96005 · Cited by 1
Yin, S., Ma, M., Huang, Z., Fan, Y., Wang, X., Song, T., & Lin, T. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.800872 · Cited by 1
Síndrome de ovario poliquístico, el riesgo cardiovascular olvidado
Corredor-Rengifo, D., Pérez, T. B., Martinez, C. A. G., & Abreu-Lomba, A. (2023) · Interdisciplinary Journal of Epidemiology and Public Health · doi:10.18041/2665-427x/ijeph.1.10262
Das polyzystische Ovarsyndrom: Aktuelle Evidenz und praktische Empfehlungen
Tan, S., Böing, C., & Führer‐Sakel, D. (2020) · Diabetologie und Stoffwechsel · doi:10.1055/a-0891-9131
Metadata
- Authors
- Javed, Z., Papageorgiou, M., Deshmukh, H., Rigby, A. S., Qamar, U., Abbas, J., Khan, A. Y., Kilpatrick, E. S., Atkin, S. L., & Sathyapalan, T.
- Affiliations
- University of Hull (GB)
- Pakistan Kidney and Liver Institute and Research Center (PK)
- Sidra Medical and Research Center (QA)
- Weill Cornell Medical College in Qatar (QA)
- Corresponding author
- Sathyapalan, Thozhukat
- ORCID
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2019-04-02
- Volume
- 90
- Issue
- 6
- Pages
- 805-813
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2922516009
- Cited by
- 121
- References
- 38
- Citations by year
- 2026: 12 · 2025: 20 · 2024: 18 · 2023: 20 · 2022: 22 · 2021: 16 · 2020: 11 · 2019: 1
- FWCI
- 11.95
- Type
- journal article
- Language
- en
- Open access
- Locations
- Clinical Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Repository@Hull (Worktribe) (University of Hull) (submittedVersion, cc-by)
- Funders
- University of Hull
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- empagliflozin, polycystic ovary syndrome, metformin, SGLT2 inhibitors, body composition, weight loss, obesity, basal metabolic rate, fat mass, waist circumference, body mass index, insulin resistance, metabolic parameters, hormonal parameters, cardiovascular risk, women's health, drug comparison, anthropometry, SGLT1 inhibition, insulin sensitivity
- MeSH terms
- Adolescent, Adult, Anthropometry, Benzhydryl Compounds, Body Composition, Cardiovascular Diseases, Drug Administration Schedule, Female, Glucosides, Hormones, Humans, Life Style, Metformin, Middle Aged, Obesity, Polycystic Ovary Syndrome, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
